Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products ...
Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...
Standard BioTools (LAB) announced that its SomaScan Platform played a pivotal role in a study published in the current issue of Nature Medicine ...
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. During ...
Zacks.com on MSN20h
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to BuyShares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from ...
Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and ...
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
Novo Nordisk made a similar case for semaglutide in a petition to the regulator last year, seeking to put the drug on an FDA list of compounds deemed to be difficult to compound, but has so far ...
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback